Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
82 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
Myocardial Ischemia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Myocardial Ischemia - Pipeline Review, H1 2015', provides an overview of the Myocardial Ischemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Myocardial Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myocardial Ischemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Myocardial Ischemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Myocardial Ischemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Myocardial Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Myocardial Ischemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of table 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Myocardial Ischemia Overview 8 Therapeutics Development 9 Pipeline Products for Myocardial Ischemia - Overview 9 Pipeline Products for Myocardial Ischemia - Comparative Analysis 10 Myocardial Ischemia - Therapeutics under Development by Companies 11 Myocardial Ischemia - Therapeutics under Investigation by Universities/Institutes 12 Myocardial Ischemia - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Myocardial Ischemia - Products under Development by Companies 16 Myocardial Ischemia - Products under Investigation by Universities/Institutes 18 Myocardial Ischemia - Companies Involved in Therapeutics Development 19 Baxter International Inc. 19 CoDa Therapeutics, Inc. 20 Lixte Biotechnology Holdings, Inc. 21 Miltenyi Biotec GmbH 22 Nyken BV 23 Opsona Therapeutics Ltd. 24 Taxus Cardium Pharmaceuticals Group Inc. 25 ViroMed Co., Ltd. 26 Myocardial Ischemia - Therapeutics Assessment 27 Assessment by Monotherapy Products 27 Assessment by Target 28 Assessment by Mechanism of Action 30 Assessment by Route of Administration 32 Assessment by Molecule Type 34 Drug Profiles 36 alferminogene tadenovec - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 AntimiR-199a - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 EP-80317 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Gene Therapy for Ischemic Heart Failure - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Humanin - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 LB-100 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 LB-102 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 MG-53 - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 NYK-1112 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 OPN-305 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Peptagon - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 PMC-6 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Protein for Myocardial Infarction and Critical Limb Ischemia - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Small Molecules to Inhibit Mst1 for Myocardial Ischemia - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 Stem Cell Therapy for Cardiovascular Disease - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 VM-202 - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Myocardial Ischemia - Recent Pipeline Updates 63 Myocardial Ischemia - Dormant Projects 69 Myocardial Ischemia - Product Development Milestones 70 Featured News & Press Releases 70 Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum 70 Sep 03, 2014: Taxus Cardium to Present at the Rodman & Renshaw 16th Annual Global Investment Conference in New York City 72 Aug 13, 2014: Taxus Cardium Announces Biological and Clinical Advances in Angiogenic Gene Therapy for Heart Disease in Journal of Cardiovascular Pharmacology 73 Jun 12, 2014: Cardium To Announce Interim Results Of Generx Angiogenic Gene Therapy Phase 3 Clinical Study At The 2014 BIO International Convention 73 Jan 27, 2014: Cardium Announces Strategic Focus On Advanced Regenerative Therapeutics Based On Generx Clinical Findings 74 May 02, 2013: Cardium Therapeutics Announces Publication Of Data On Generx In Journal Molecular Therapy 75 Nov 19, 2012: Cardium Therapeutics Announces Patent Award For Rights To Cardiovascular Gene Therapy For Treatment Of Heart Disease 76 Oct 25, 2012: Cytori Announces Japanese Approval For Clinical Studies Of Cardiovascular And Chronic Liver Disease Cell Therapy 78 May 18, 2012: New drug discovery collaborations with Queen Mary University of London launched 78 Mar 20, 2012: Cardium Therapeutics Initiates Generx Phase III Clinical Registration Study 79 Appendix 81 Methodology 81 Coverage 81 Secondary Research 81 Primary Research 81 Expert Panel Validation 81 Contact Us 81 Disclaimer 82
List of Tables Number of Products under Development for Myocardial Ischemia, H1 2015 9 Number of Products under Development for Myocardial Ischemia - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 11 Number of Products under Investigation by Universities/Institutes, H1 2015 12 Comparative Analysis by Late Stage Development, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Comparative Analysis by Early Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Development by Companies, H1 2015 (Contd..1) 17 Products under Investigation by Universities/Institutes, H1 2015 18 Myocardial Ischemia - Pipeline by Baxter International Inc., H1 2015 19 Myocardial Ischemia - Pipeline by CoDa Therapeutics, Inc., H1 2015 20 Myocardial Ischemia - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 21 Myocardial Ischemia - Pipeline by Miltenyi Biotec GmbH, H1 2015 22 Myocardial Ischemia - Pipeline by Nyken BV, H1 2015 23 Myocardial Ischemia - Pipeline by Opsona Therapeutics Ltd., H1 2015 24 Myocardial Ischemia - Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H1 2015 25 Myocardial Ischemia - Pipeline by ViroMed Co., Ltd., H1 2015 26 Assessment by Monotherapy Products, H1 2015 27 Number of Products by Stage and Target, H1 2015 29 Number of Products by Stage and Mechanism of Action, H1 2015 31 Number of Products by Stage and Route of Administration, H1 2015 33 Number of Products by Stage and Molecule Type, H1 2015 35 Myocardial Ischemia Therapeutics - Recent Pipeline Updates, H1 2015 63 Myocardial Ischemia - Dormant Projects, H1 2015 69
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.